Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Acta Neurochir (Wien) ; 164(5): 1365-1373, 2022 05.
Article in English | MEDLINE | ID: mdl-35257217

ABSTRACT

BACKGROUND: Primary CNS lymphoma (PCNSL) is a highly aggressive non-Hodgkin lymphoma (NHL) that occurs in the CNS (e.g. brain, meninges, spinal cord, cerebrospinal fluid, or intraocular involvement) in the absence of systemic NHL. Tumor resection does not improve survival, and neurosurgical intervention is generally limited to stereotactic biopsy to provide a histopathological diagnosis. OBJECTIVE: The objective of this single-center study was to evaluate the management and outcome of PCNSL patients diagnosed by biopsy, using overall survival and progression-free survival as endpoints. METHODS: At our department of neurosurgery, 140 patients were diagnosed with PCNSL by biopsy between January 1, 2009, and December 31, 2018. Of these, 37 patients were included in the study and were divided into three groups according to their postoperative therapy. RESULTS: Median OS was 35.7 months for the intensive treatment group, 29.5 months for the moderate treatment group, and 8.6 months for the palliative treatment group. The intensive and moderate treatment groups had similar progression-free survival, while the palliative treatment group had poor overall and progression-free survival. Six patients were long-term survivors (> 80 months). Age under 65 years was the main significant parameter affecting overall survival. CONCLUSION: In this cohort, patients with PCNSL had an overall fair prognosis if they (1) were under 65 years old, (2) had a performance score < 2 at the time of diagnosis, and (3) received either intensive or moderate chemotherapeutic treatment. Biopsy is still the primary diagnostic tool; other methods have been investigated but are not yet recommended.


Subject(s)
Central Nervous System Neoplasms , Lymphoma, Non-Hodgkin , Aged , Brain/pathology , Central Nervous System Neoplasms/diagnosis , Central Nervous System Neoplasms/therapy , Cohort Studies , Humans , Lymphoma, Non-Hodgkin/diagnosis , Lymphoma, Non-Hodgkin/pathology , Lymphoma, Non-Hodgkin/therapy , Neurosurgical Procedures/methods , Prognosis , Progression-Free Survival , Retrospective Studies , Treatment Outcome
2.
Surgeon ; 18(6): 344-348, 2020 Dec.
Article in English | MEDLINE | ID: mdl-32044289

ABSTRACT

INTRODUCTION: Glioblastoma has a high mortality rate. Current treatment includes largest possible surgical resection of the tumour using neuronavigation and fluorescence to better identify tumour tissue. In recent years, sodium fluorescein has been reintroduced in neurosurgery as a fluorescence to increase the resection rate. In this study we aimed to measure the surgeons experience of using sodium fluorescein to locate and remove tumour tissue. Furthermore we describe a case of sodium fluorescein tissue distribution. MATERIAL AND METHODS: 13 patients with glioblastoma and seven patients with cerebral metastases undergoing surgical resection were included. Surgery was performed using microscope alternating between white light and the YELLOW 560 filter, which visualized sodium fluorescein. Surgeons graded its usability in terms of location and removal on a scale from one to four. The resection rate was determined by neuroradiologists. Tissue samples obtained during surgery were analysed in relation to fluorescence and dysmorphic cells. RESULTS: Surgeons reported high usability in terms of location and removal of tumours using sodium fluorescein with medians of four in all groups, except for sub-total resections which had a median of three. Surgical complications were minimal and both resection rate and survival rate was within international standards. Histological analysis showed a visual correlation between tumorous tissue and intensity of fluorescence. CONCLUSION: Sodium fluorescence is an effective and useful tool for surgeons during fluorescence-guided surgery for the resection of glioblastoma and cerebral metastases.


Subject(s)
Brain Neoplasms/surgery , Fluorescein , Fluorescent Dyes , Glioblastoma/surgery , Aged , Aged, 80 and over , Brain Neoplasms/mortality , Brain Neoplasms/pathology , Cohort Studies , Female , Glioblastoma/mortality , Glioblastoma/pathology , Humans , Male , Middle Aged , Practice Patterns, Physicians'
3.
Acta Neurochir (Wien) ; 161(3): 555-565, 2019 03.
Article in English | MEDLINE | ID: mdl-30756241

ABSTRACT

BACKGROUND: This study aimed to investigate the incidence of residual tumour after resection of brain metastases using early postoperative magnetic resonance imaging (MRI) and the influence of residual tumour on overall patient survival. METHODS: Data from 72 consecutive adult patients undergoing surgery for cerebral metastases over an 18-month study period were retrospectively collected. Early postoperative MRI was used to determine the presence of postoperative residual tumour. Patients were divided into three groups according to the presence of tumour remnant on early postoperative MRI: "no residual tumour", "non-measurable residual tumour" and "measurable residual tumour". Survival analysis (mean estimate survival time) was performed using the Kaplan-Meier and log-rank (mantel cox) tests and compared between groups. Surgical reports were evaluated with regard to the surgeon statement about intraoperative extent of resection (EOR) and compared with the presence of tumour remnant found on the early postoperative MRI. RESULTS: Sixty-eight procedures were followed by early postoperative MRI. MRI verified the presence of "measurable residual tumour" following 15 procedures (22%). MRI confirmed complete resection in 57%. Gross total resection was described by the operating surgeon in 85% of the procedures. There was a significant difference in survival time after surgery between the group having no residual tumour on MRI and the group with measurable residual tumour (p = 0.025). This difference could not be explained by the differences in postoperative radiation therapy. The longest survival was found in patients with non-measurable and no residual tumour on early postoperative MRI, who also received postoperative radiotherapy. CONCLUSION: Residual tumour was seen on MRI after 22% of the procedures. The intraoperative assessment of EOR performed by the surgeon diverged from the early postoperative MRI in 40% of procedures. Correct assessment of residual tumour thus requires early postoperative MRI. Measurable residual tumour on early postoperative MRI was associated with shorter overall survival independent on postoperative radiotherapy.


Subject(s)
Brain Neoplasms/surgery , Magnetic Resonance Imaging/methods , Postoperative Complications/epidemiology , Adult , Aged , Brain Neoplasms/diagnostic imaging , Brain Neoplasms/secondary , Female , Humans , Male , Middle Aged , Neoplasm, Residual , Neurosurgical Procedures/adverse effects , Neurosurgical Procedures/methods , Postoperative Complications/diagnostic imaging , Survival Analysis
4.
Ugeskr Laeger ; 177(26)2015 Jun 22.
Article in Danish | MEDLINE | ID: mdl-26550627

ABSTRACT

Thrombosis of the cerebral sinuses most often affects younger adults. Headache is a common complaint and can be accom­panied by vomiting and papilloedema. The diagnosis rests on magnetic resonance imaging and the treatment consists of heparin or low-molecular weight heparin followed by vitamin K antagonists for three months or more. In fulminant cases local thrombolysis is administered, while symptomatic treatment for increased intracranial pressure is given. In retrospective analyses this approach has been associated with a good outcome ­ even in cases treated by decompressive craniectomy.


Subject(s)
Sinus Thrombosis, Intracranial , Adult , Anticoagulants/therapeutic use , Heparin/therapeutic use , Humans , Magnetic Resonance Angiography , Magnetic Resonance Imaging , Sinus Thrombosis, Intracranial/diagnosis , Sinus Thrombosis, Intracranial/diagnostic imaging , Sinus Thrombosis, Intracranial/drug therapy , Sinus Thrombosis, Intracranial/physiopathology , Vitamin K/antagonists & inhibitors , Young Adult
5.
Ugeskr Laeger ; 176(33)2014 Aug 11.
Article in Danish | MEDLINE | ID: mdl-25293408

ABSTRACT

Thrombosis of the cerebral sinuses most often affects younger adults. Headache is a common complaint and can be accompanied by vomiting and papilloedema. The diagnosis rests on magnetic resonance imaging and the treatment consists of heparin or low-molecular weight heparin followed by vitamin K antagonists for three months or more. In fulminant cases local thrombolysis is administered, while symptomatic treatment for increased intracranial pressure is given. In retrospective analyses this approach has been associated with a good outcome - even in cases treated by decompressive craniectomy.


Subject(s)
Sinus Thrombosis, Intracranial , Adult , Anticoagulants/therapeutic use , Heparin/therapeutic use , Humans , Magnetic Resonance Imaging , Sinus Thrombosis, Intracranial/diagnosis , Sinus Thrombosis, Intracranial/drug therapy , Sinus Thrombosis, Intracranial/physiopathology , Vitamin K/antagonists & inhibitors , Young Adult
6.
Ugeskr Laeger ; 174(10): 630-3, 2012 Mar 05.
Article in Danish | MEDLINE | ID: mdl-22395010

ABSTRACT

Recent research has revealed the existence of a class of small non-coding RNAs, known as microRNAs. These microRNAs are deregulated in various cancers including gliomas. MicroRNAs have been suggested to be important in cancer stem cell biology and in proliferation and chemosensitivity of cancer cells. This makes microRNAs obvious targets for novel therapeutic strategies. In the present article we focus on the role of microRNAs in cancer cells and cancer stem cells as well as the possible therapeutic approaches exploiting this knowledge to improve future glioma therapy.


Subject(s)
Brain Neoplasms/drug therapy , Glioma/drug therapy , MicroRNAs/genetics , Antineoplastic Agents/administration & dosage , Brain Neoplasms/genetics , Convection , Drug Delivery Systems/methods , Gene Expression Regulation, Neoplastic/genetics , Glioblastoma/drug therapy , Glioblastoma/genetics , Glioma/genetics , Humans , MicroRNAs/drug effects , MicroRNAs/physiology , Neoplastic Stem Cells/drug effects , Neoplastic Stem Cells/physiology
SELECTION OF CITATIONS
SEARCH DETAIL